The frequency and T-cell receptor beta-chain variable (TCRBV) patterns of peripheral CD4
INTRODUCTION
Hepatitis B virus (HBV) infection remains a global health problem with more than 350 million chronically infected individuals worldwide. Chronic HBV infection can lead to liver cirrhosis, liver failure, and hepatocellular carcinoma.
1,2 Antiviral treatment is critical for patients with chronic hepatitis B (CHB), and it can provide long-term suppression of HBV replication, delay disease progression, and improve the quality of life and survival time for patients with chronic HBV infections. 3 Tenofovir disoproxil fumarate (TDF) is a potent inhibitor of HBV replication that produces a high level of virological suppression with little genotypic resistance. [4] [5] [6] Hepatitis B e antigen (HBeAg) seroconversion (SC) is a satisfactory treatment endpoint for HBeAg-positive (HBeAg 1 ) 11, 18 In this study, we examined the dynamic frequency of peripheral Tregs in HBeAg 1 CHB patients during TDF treatment and longitudinally analyzed the dynamic relationship between the percentage of Tregs and HBV DNA levels in patients who have undergone SC and in those who have not. Furthermore, we preliminarily analyzed the relationship between the number of skewed TCRBV patterns (monoclonal or oligoclonal expansion) in the Tregs and the HBV DNA or alanine aminotransferase (ALT) levels in seroconverting and non-seroconverting CHB patients during TDF treatment. Additionally, the molecular profiles of monoclonal TCRBV families in the preferred Tregs were also determined.
MATERIALS AND METHODS

Subjects
Thirty-seven HBeAg 1 outpatients with CHB were admitted to the Department of Infectious Disease, the First Affiliated Hospital, College of Medicine, Zhejiang University, between November 2011 and August 2012. All subjects were documented to be positive for HBsAg for at least 6 months before screening, and, simultaneously, their HBV DNA levels were higher than 10 7 copies/ml; the inclusion criteria and the patient cohort composition are referred to in previous reports. 19, 20 In addition, patients with diabetes, severe systemic illness, neoplasm, pregnancy and/or breast-feeding in women, or who were receiving immunosuppressive therapy were excluded. All subjects were orally treated with 300 mg of TDF-naive daily and were scheduled to continue the TDF treatment for 5 years in our original scheme. Blood samples were taken at baseline and at follow-up visits at weeks 4, 12, 24, 36, 48, 60, 72, 84 , and 96. At week 96, only 32 patients with complete experimental data remained in this study (five withdrew, including two who withdrew their consent, two who were lost to follow-up, and one whose protocol deviated), and their baseline clinical characteristics are shown in Supplementary Table S1 . The 32 patients (age range: 21-50) were classified as having HBeAg SC (n 5 12) or no HBeAg SC (n 5 20), depending on whether they had undergone HBeAg loss (HBeAg loss (quantitative HBeAg ,1.00 S/CO) and were positive for anti-HBeAg conversion (quantitative hepatitis B e antigen antibody (HBeAb) ,1.00 S/CO)) by week 72. Twenty healthy donors (HDs; age range: 23-50 years) were selected for controls and were sex-and age-matched with the CHB groups. The recruited HDs had no previous history or current evidence of liver disease (they were negative for all HBV serological markers) and had normal serum ranges for transaminases. Written informed consent was obtained from all subjects prior to enrollment. The study was conducted according to the guidelines of the Declaration of Helsinki. The First Affiliated Hospital, College of Medicine, Zhejiang University medical ethics committee approved this study.
Assessment of biochemical, serological, and virological indicators Serum ALT and other biochemical indicators of liver function, as well as serological and virological markers, were determined in the central laboratory of the First Affiliated Hospital, College of Medicine, Zhejiang University, as was described in detail in our previous study. 19 Separation of peripheral blood mononuclear cells Peripheral blood mononuclear cells (PBMCs) were isolated from 10 ml of fresh EDTAK 2 anti-coagulant-treated blood using Ficoll-Paque (StemCell Technologies, Vancouver, Canada) density gradient separation.
Isolation of Tregs CD4
1
CD25
1 Tregs were isolated from fresh PBMCs. Briefly, CD4
1 T cells were isolated from PBMCs by CD4-negative selection, followed by CD25-positive selection using anti-CD25 magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany), according to the manufacturer's instructions. The CD4
1
CD25
1 T cells were left overnight in supplemented media, and cells, after spontaneous detachment from the beads, were exhaustively washed to separate cells expressing high levels of CD25. The CD4
1
CD25
2 fraction was obtained by depleting the negatively selected CD4
1 cell fraction of CD25 1 cells using positive-selection beads. The CD4
1
CD25
1 Treg purification method resulted in a Treg fraction containing more than 90% pure CD4 1 CD25 high Tregs.
Flow cytometric analysis
To stain CD4
1
CD25
1 Tregs, peridinin chlorophyll (PerCP)-labeled anti-CD3, fluorescein isothiocyanate (FITC)-labeled anti-CD4, and phycoerythrin (PE)-labeled anti-CD25 antibodies were used. More detailed procedures were described in our previously published protocol. 17 Only CD4 1 T cells expressing a high level of CD25 were counted as CD4 1 CD25 1 Tregs. Intracellular staining of forkhead helix transcription factor P3 (FoxP3) was conducted using a fluorescently labeled anti-CD3 antibody, and anti-CD4 and anti-CD25 antibodies were used for surface marker staining, followed by FITC-labeled anti-FoxP3 (eBiosciences, San Diego, CA, USA) staining after permeabilization. Other fluorochrome-conjugated antibodies specific for surface markers included PerCP-anti-human leukocyte antigen (HLA)-DR, FITC-anti-CD45RA, and allophycocyanin-anti-CD45RO, while PE-anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) was used to stain an intracellular marker. After staining, the cells were fixed and analyzed using FACSCalibur and CellQuest software (BD Biosciences, Franklin Lakes, NJ, USA). 17 Isotype-matched antibodies were used as controls for all samples.
Total RNA extraction and synthesis of cDNA Total RNA was extracted from purified CD4 1 CD25 high Tregs using the SV Total RNA Isolation System (Promega, Madison, WI, USA) according to the manufacturer's instructions. Details concerning the synthesis of cDNAs were presented in our previous report. 21 Analysis and identification of skewed TCRBV families by GMSP GoTaq qPCR Master Mix (Promega) was used for the GMSP assay. A 25-ml master mix for each of the 28 reactions contained 0.4 mM reverse primer TCRBC and 50-150 ng of cDNA as a template to generate GMSPs as previously described. 22 Skewed TCRBV gene families were defined using the profile of each GMSP image developed using Opticon Monitor 3.0 software attached to a real-time PCR machine (MJ Opticon 2 DNA engine, Bio-Rad, Hercules, CA, USA). The TCRBV families fell into three categories: oligoclonal, monoclonal, and normal expansion; more details were described in our previously published report. 21 The TCRBV families with oligoclonal or monoclonal expansion were classified into skewed categories, and normal expansion (no skew) was considered to be present if the height of any secondary peak was more than 5/8 the height of the main peak in a GMSP shape, which is an advancement to our previously published protocols. 23 Sequencing monoclonal TCRBV families Any TCRBV gene family showing a single peak on the GMSP profile was selected for cloning and sequencing to determine the degree of homogeneity within the CDR3 region. Detailed protocols were presented in our previous reports. 17, 24 Statistical analysis All data were analyzed using SPSS software version 19.0 (SPSS Inc., Chicago, IL, USA). Differences in the number of skewed TCRBV families for CD4
1
CD25
1 Tregs from seroconverting or non-seroconverting patients were analyzed using KruskalWallis or Mann-Whitney tests. Categorical variables were analyzed using a chi-squared test or Fisher's exact test. A P value ,0.05 was considered to be statistically significant. Correlations between any two parameters were determined using Spearman's bivariate correlation.
RESULTS
The HBeAg
1 CHB patients enrolled in this study had never received antiviral therapy. No other liver-related complications occurred during treatment, and no serious adverse events or hepatitis flares were observed throughout the entire 96-week TDF treatment.
Changing HBV DNA loads in SC or non-SC groups In the present study, HBeAg SC was observed beginning at week 24 and also occurred at follow-up treatment time points (four patients at week 24; three patients each at weeks 36 and 48; one patient each at weeks 60 and 72). We found that any differences in HBV DNA levels between the SC and non-SC groups at baseline were significant ( Figure 1a , P 5 0.03). During treatment with TDF, HBV DNA levels declined consistently by almost three log10 from pretreatment levels (baseline) by week 4 in both the SC and non-SC groups, and could not be detected after week 72 in any seroconverting patients. In non-seroconverting patients, the average level of HBV DNA decreased until week 60, but HBV DNA could be detected throughout the entire 96-week TDF treatment ( Figure 1b ).
Similar frequencies of CD4
1
CD25
1 Tregs in SC and non-SC groups at baseline We quantified the CD4 1 CD25 high (fluorescence intensity of CD25 . 100) Treg population level in the total CD4 1 population. This value has been used previously to represent the quantity of CD4 1 CD25 1 Tregs in HBV-infected patients. 25 The CD4 1 CD25 high subpopulation expressed a significantly higher level of intracellular FoxP3 and CTLA-4, and of surface HLA-DR and CD45RO, but a lower level of surface CD45RA, compared with the CD4 1 CD25 2 subpopulation (Supplementary Figure S1) .
Our results indicated that seroconverting and non-seroconverting patients showed no remarkable difference in the level of CD4 1 CD25 1 Tregs at pretreatment (baseline; mean, SC 5 5.46%; non-SC 5 5.63%, P 5 0.379), and the levels in both groups were higher than that of the healthy controls (mean, 3.16%, P , 0.001, 0.001; Figure 2a ).
Kinetic levels of peripheral Tregs in seroconverting and nonseroconverting patients
Changes in the percentage of Tregs over time in patients receiving TDF therapy are displayed in Figure 2 . We found that the numbers of Tregs in seroconverting and non-seroconverting patients before TDF treatment were significantly greater than those in the HDs. Following treatment with TDF, the percentage of CD4 1 CD25 1 Tregs gradually declined compared with that before treatment. Compared with the number of Tregs before treatment, a significant reduction in Tregs was found beginning at week 24 in the SC group, and this average was restored to a normal range beginning at this time point (Figure 2b ). However, non-seroconverting patients showed a modest decrease in Treg levels during therapy until the beginning of week 60, and while their average Treg levels were significantly lower than those at baseline, the levels never reached the normal range (Figure 2a , b, and c). Furthermore, beginning at week 24, the Treg levels of seroconverting patients were significantly lower than those of non-seroconverting patients at each time point (Figure 2a) . Additionally, the percentage of SC and non-SC patients reaching the normal range of Treg frequency was determined (Figure 2d ), and the sequential representative scatter plots for CD4
1
CD25
high Tregs from representative SC and non-SC patients undergoing TDF treatment are provided for each time point (Supplementary Figure S2) .
Relationship between serum HBV DNA or ALT levels and circulating Treg frequencies There was a significant positive correlation between changes in serum HBV DNA loads and the circulating CD4 1
1 Treg frequency in seroconverting patients during TDF therapy (R 5 1.000, P , 0.001; Figure 3a) , and a similar relationship was found in non-seroconverting patients (R 5 0.891, P 5 0.001; Figure 3b ). In the patients receiving TDF, there was no decrease in the percentage of Tregs at week 4 (baseline vs. 4 weeks; SC, 5.46 vs. 5.26%; non-SC, 5.63 vs. 5.62%; P . 0.05), despite the significant declines in HBV DNA in these patients from baseline to week 4 (P , 0.001). However, by week 24, there was a significant reduction in Tregs in the SC group receiving TDF treatment (4 vs. 24 weeks; 5.26 vs. 3.65%; x 2 , P 5 0.003), but not in the non-SC group (4 vs. 24 weeks; 5.62 vs. 4.91%; x 2 , P 5 0.176). In addition, a significant correlation between changes in ALT and Treg levels was observed in seroconverting patients (R 5 0.952, P , 0.001; Figure 3c ), but this correlation was not significant in the non-seroconverting patients (R 5 0.600, P 5 0.067; Figure 3d ).
Longitudinal changes in the number of skewed TCRBV families of CD4 Figure S3) . In the SC group, the number of skewed TCRBV families consistently declined, while the number of skewed families in the non-SC group declined and then rebounded after week 36. As the reduction proceeded, the number of skewed TCRBV families in the non-SC group was significantly higher than that in the SC group beginning at week 48 (P , 0.001).
Relationship between serum HBV DNA or ATL levels and the number of skewed TCRBV families A decline in the number of skewed TCRBV families in CD4 1 CD25 1 Tregs was associated with a reduction in serum HBV DNA or ALT levels. In the SC group, the levels of TCRBV and HBV DNA declined in parallel and were significantly correlated (R 5 0.976, P , 0.001; Figure 4a ). In the non-SC group, however, the correlation between the skewed TCRBV families and the HBV DNA level was not significant (R 5 0.612, P 5 0.060; Figure 4b ). As with the changes in the HBV DNA level, there was a significant relationship between the number of skewed TCRBV families and the ATL level (R 5 0.894, P 5 0.003; Figure 4c ) in the SC group. Similarly, the correlation between these two parameters was also significant in the non-SC group (R 5 0.661, P 5 0.038; Figure 4d ). Characteristics of skewed TCRBV families in seroconverting and non-seroconverting patients The incidence of skewed TCRBV families was compared for the SC and non-SC groups at three time points (baseline, week 72, and week 96) during the follow-up treatment period. There were differences between seroconverting and non-seroconverting patients in terms of the levels of monoclonality or oligoclonality among the 24 TCRBV families detected in CD4 1
1 Tregs. Six TCRBV families (BV3, BV11, BV12, BV14, BV20, and BV24) were more prevalent than other TCRBV members in seroconverting patients at baseline. Similarly, seven TCRBV families (BV3, BV5.1, BV11, BV12, BV13.1, BV15, and BV22) were more frequent than other TCRBV members in non-seroconverting patients (Table 1) . Moreover, three TCRBV families (BV12, BV15, and BV22) were expressed at a high frequency throughout the 96-week period in non-seroconverting patients, but no TCRBV families were prevalent in seroconverting patients at weeks 72 or 96.
Relatively conserved CDR3 motifs for monoclonal Tregs in the SC and non-SC groups Representative amino acid sequences for TCRBV CDR3 from seroconverting and non-seroconverting patients during treatment are shown in Table 2 . We found that the frequently observed TCRBV5.1 exhibited a relatively conserved CDR3 (LDYS-XXXX with BJ1.3) in non-seroconverting patients, and TCRBV11 CDR3 primarily used 'XX-NEQ with BJ2.1' in non-seroconverting patients. In addition, TCRBV15 and BV22 were found at a high frequency in non-seroconverting patients during treatment and prevalently expressed 'XXXXXXX-NEQ with BJ2.1' and 'XXXXXX-VVNEQ with BJ2.1', respectively. Moreover, TCRBV24 exhibited the relatively conserved CDR3 (XX-SSGLE-XXX with BJ2.1 or BJ2.5) in seroconverting patients.
DISCUSSION
It is well known that antiviral therapy can control the progression of chronic HBV infection and contribute to a reduction in the morbidity and mortality of HBV-related disease. TDF is a new nucleotide reverse transcriptase inhibitor with a high genetic barrier to resistance and is an efficacious reagent. 5, 26, 27 In this study, we evaluated longitudinal changes in the frequencies of peripheral Tregs and skewed Treg TCRBV families for HBeAg 1 nucleos(t)ide analogue-naive CHB patients during 96 weeks of TDF treatment. We determined the characteristic 
CD25
1 Treg percentages between seroconverting and non-seroconverting patients during TDF treatment (a); Changing percentages of CD4
1
CD25
1 Tregs for each subject with SC (b) and non-SC (c); Proportion of patients with normalization of Treg frequency during TDF treatment (d). The horizontal lines indicate the mean for each time point from the SC and non-SC groups during treatment (b and c); Treg frequency that is within the range of normal levels (from HDs) is classified as normalization of Treg frequency (d). *P , 0.05 and **P , 0.01 when comparing the Treg frequency between non-seroconverting and seroconverting patients at the same time point, respectively; ***P , 0.001 when comparing the Treg frequency of the non-SC group at each time point during treatment with that of the HD group. kinetic patterns of Treg percentages and the number of skewed Treg TCRBV families, as well as some distinctive TCRBV profiles, in seroconverting and non-seroconverting patients. These findings could be used to predict HBeAg SC in CHB patients during 96 weeks of TDF treatment, and they could promote the development of CHB immunotherapy.
Antiviral efficacy is closely associated with the restoration of cellular immune function in CHB patients, particularly for the HBV-specific T-cell response. 28 Tregs are important immune regulatory cells that can prevent excessive pathological damage by inhibiting HBV-specific CD8 1 T-cell activation, which otherwise may aid persistent viral infection in CHB patients. 29 In the present study, Treg percentages were higher in seroconverting and non-seroconverting patients at pretreatment (baseline) than in the HD group. The average Treg level returned to normal at week 24 in seroconverting patients, and it remained at this level during the antiviral treatment period. However, the Treg level declined slightly in non-seroconverting patients and never reached the normal level, which is consistent with Ma's study, 30 and suggests that antiviral efficacy is closely related to the Treg frequency.
HBeAg SC is considered to be an important surrogate marker for assessing the durability and efficacy of antiviral therapy in HBeAg 1 CHB patients. 31 However, there are few surrogate seromarkers for predicting SC in HBeAg 1 CHB patients undergoing TDF treatment. 32 A study concerning interferon-based therapies for CHB infection reported that there were several factors associated with a higher likelihood of HBeAg SC, including elevated serum ALT activity and lower levels of HBV DNA. 33 Our results are consistent with this conclusion for ALT, as indicated by the higher ALT level in the SC group compared with the non-SC group (Supplementary Figure S4) . Additionally, it is generally believed that serum ALT levels reflect the degree of hepatocyte damage caused by the host immune response against HBV-related antigens, and the immune response may suppress HBV replication and promote subsequent HBeAg SC. Therefore, our results are in accordance with a previous study that showed there was a higher rate of HBeAg loss among HBeAg 1 patients treated with peginterferon rather than entecavir, which may be partially related to their higher baseline ALT levels. 34 In addition, our results showed that the correlation between the ALT and Treg levels differed between the SC and non-SC groups, which further suggests that antiviral efficacy and HBeAg SC are closely associated with Treg frequencies and that a specific TCRBV family was involved. This relationship and the dominance of the antigen-specific regulatory T-cell response in SC and non-SC patients should be explored in future studies that include more cases. However, the relationship between the HBV DNA and Treg levels was similar in the SC and non-SC groups. TDF can directly inhibit HBV DNA replication, thereby resulting in a decline in HBV DNA levels, and the reduction of HBV DNA can partially restore adaptive immune responses and reduce Treg levels.
11
It is well known that the restoration of HBV antigen-specific T cells plays a vital role in HBeAg SC during antiviral treatment, and the specificity of T cells is solely dictated by the TCR they clonally express. 7, 15 It was reported that the TCR repertoire of tumor-infiltrating regulatory T lymphocytes was skewed toward public sequences. 35 In the current study, we found three TCRBV families (BV12, BV15, and BV22) to be more prevalent during the course of TDF treatment in non-seroconverting patients. Additionally, three TCRBV families (BV14, BV20, and BV24) were found more often in seroconverting patients at baseline, but there was no significant difference between these families and other TCRBV members at weeks 72 or 92. These results indicate that the occurrence of SC may be associated with three TCRBVs in HBeAg 1 patients during TDF treatment, and the prevalence of TCRBV12, BV15, and BV22 may be related to the absence of HBeAg SC in patients receiving TDF, although this finding should be confirmed in future studies.
Moreover, TCRBV families with relatively conserved CDR3 motifs may be involved in the immunological process of HBeAg SC and may also be potential targets for personalized treatment of CHB. 36 However, additional studies of immune activation markers would be valuable for determining the correlation between these factors and the changes in Tregs and TCRBV families, which will enable the identification of prevalent TCRBV families that are specific to HBV, as well as their degree of conservation. Therefore, the results will contribute to therapy for HBV-related tumors by enabling the engineering of T-cells that express specific TCRBV families. 37 It may be possible to develop monoclonal antibodies against TCRBV and inhibit the immunosuppressive activity of Tregs, 38 which will contribute to immunotherapy for CHB patients. 39 In the future, the specificity of TCRBV families could be determined using gene transfection and cytotoxicity tests. Additionally, the determined prevalence of TCRBV families can provide a vital clue for finding a TCRBV family-specific HBV peptides, which will contribute to the development of engineered T-cell therapies for hepatitis B. and non-seroconverting patients further indicate that a TCRBV family profile analysis could be used to understand the immune response that accompanies SC. In addition, the different dynamic patterns of skewed TCRBV numbers between seroconverting and non-seroconverting patients during TDF treatment, which is consistent with biased TCR usage, could have important implications for disease pathogenesis and prognosis. 41, 42 These results suggest that the kinetic patterns of peripheral Tregs and TCRBV families could be potential predictive factors.
The small number of enrolled patents, which occurred because some patients dropped out during treatment for various reasons, is a limitation of this study. In future studies, we will continue to research the relationship between the profile of skewed TCRBV families and the progression of CHB in patients receiving antiviral therapy and will use a larger number of cases and a longer observation time. Additionally, we analyzed the TCRBV repertoire of purified Tregs expressing high levels of CD25 in patients who had undergone TDF treatment for CHB. This cell subpopulation contains the vast majority of cells with regulatory activity, 43 as we confirmed by FoxP3, CTLA-4, HLA-DR, CD45RO, and CD45RA staining.
In summary, a dynamic analysis of peripheral Treg frequencies may be used to predict HBeAg seroconversion in nucleos(t)ide analogue-naive CHB patients during TDF therapy. The finding of several specific TCRBV families and their conserved CDR3 motifs could contribute to the development of individual treatments for patients with chronic HBV infection; additionally, it could There could be a type 1 error problem when comparing the incidence of skewed TCRBVs for the SC and non-SC groups at a specified time point. GMSP, gene melting spectral pattern; HBeAg, hepatitis B e antigen; SC, HBeAg seroconversion; non-SC, non-HBeAg seroconversion; TCRBV, T-cell receptor beta-chain variable; TDF, tenofovir disoproxil fumarate; Treg, regulatory T-cell. a The number of patients with a skewed (oligoclonal or monoclonal) TCRBV is summarized during TDF treatment (baseline, 72 weeks, 96 weeks). b The number (percentage) of patients with any skewed TCRBV families among total detected samples. Samples with normal GMSP are excluded in the average ratio calculation, and the normal pattern of GMSP means that there is no monoclonal or oligoclonal pattern in any TCRBV family in a patient. c No monoclonal TCRBV family was detected at this time point. d There was no significant difference between the two groups (P . 0.05 by x 2 test). e,f The average number of skewed TCRBV gene families was lower in the SC group than in the non-SC group after TDF treatment for 72, 96 weeks (P , 0.01 by x 2 test).
facilitate the use of Tregs for the treatment of autoimmune diseases, graft vs host disease, and cancer. 44 In addition, TDF achieved high rates of HBV suppression for up to 96 weeks of therapy among naive CHB patients, and no drug resistance was observed during TDF treatment. When the GMSP of a TCRBV family was classified as monoclonal expansion, the PCR product was re-amplified and cloned, followed sequenced. The identical amino acids in CDR3 sequences are underlined. Only the amino acid sequences of the max ratio of CDR3 are shown. BJ, T-cell receptor beta-chain joint fragment; CDR3, complementarity-determining region 3; non-SC, non-HBeAg seroconversion; SC, HBeAg seroconversion; TCRBV, T-cell receptor beta-chain variable; Tregs, regulatory T-cells; Vbeta, T-cell receptor beta-chain variable fragment. a The time point was baseline, unless otherwise indicated in brackets.
